Business
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapi...
About this update from Silo Wellness Inc
[{"type":"text","content":"Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics \nSPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders. Recent national media coverage has underscored growing momentum at the federal level to evaluate reforms related to psychedelic compounds for medical use—particularly in areas such as post-traumatic stress disorder (PTSD), depression, and anxiety. On Saturday, April 18, 2026, President Trump signed an executive order directing multiple U.S. government agencies to accelerate research into psychedelic therapies and patient access. Silo Pharma’s lead program, SPC-15, is an intranasal prophylactic treatment targeting PTSD, designed to leverage rapid nose-to-brain delivery for enhanced therapeutic effect and patient compliance. The program is being advanced under a 505(b)(2) regulatory pathway, potentially enabling a streamlined development timeline. “Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions,” said Eric Weisblum, CEO of Silo Pharma. “We believe Silo is well positioned with SPC-15 and it broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment.” Key Highlights of SPC-15 (PTSD Program): Designed as a novel serotonin 4 (5-HT4) receptor agonistTargeting prophylactic treatment of PTSD and stress-induced disordersAdministered via an intranasal formulation designed for rapid CNS deliveryBacked by intellectual property licensed from Columbia UniversityPreparing for IND engagement with the FDAAdvanced drug delivery strategyPartnership for optimized intranasal device developmentFocus on nose-to-brain delivery platforms, a rapidly emerging...